Kelyniam Global Business Summary

Kelyniam Global, Inc. (KLYG) operates a specialized medical technology business model focused on the rapid design, precision engineering, and distribution of patient-specific cranial and craniofacial implants. The company generates revenue primarily through transaction-based sales of custom prosthetics to hospitals, health systems, and neurosurgeons, leveraging a proprietary CAD/CAM manufacturing process that enables a market-leading 24-to-48-hour delivery window. Its business is divided into two primary segments: the core Custom PEEK (Polyether ether ketone) implant line, which features a patented Integrated Fixation System (IFS), and a growing Regenerative Medicine division. This secondary segment includes the exclusive U.S. distribution of bioresorbable scaffolds from Osteopore Ltd. and hydroxyapatite implants from Finceramica. Kelyniam competes directly with diversified medical device giants such as Stryker Corporation, Zimmer Biomet, DePuy Synthes (Johnson & Johnson), and Medtronic, positioning itself as a high-agility niche leader that prioritizes rapid-response surgical solutions and advanced osteointegrative materials. The company is led by a veteran executive team with deep roots in healthcare operations and financial management. Chairman and CEO Ross Bjella, who previously served as CEO of Alithias and DDN, oversees the strategic direction and was instrumental in the company's initial regulatory clearances. Chief Financial Officer Terrance Kurtenbach brings significant pedigree as a former U.S. Global Managing Partner at Deloitte, where he led the Life Sciences and Healthcare Tax practice. Desiree Webb serves as the Chief Operating and Revenue Officer, drawing on over 26 years of experience, including a tenure as Vice President of Neuroscience and Orthopedics at HCA Healthcare. Founded by James Ketner, the company has recently strengthened its capital structure through a 2024 private investment to public entity (PIPE) closure and an uplisting to the OTCID market tier, reflecting increased transparency for its institutional and accredited investor base.